Detalles de la búsqueda
1.
Cortisol as Biomarker for CYP17-Inhibition is Associated with Therapy Outcome of Abiraterone Acetate.
Pharm Res
; 40(12): 3001-3010, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37821768
2.
Testosterone analysis in castrated prostate cancer patients: suitability of the castration cut-off and analytical accuracy of the present-day clinical immunoassays.
Clin Chem Lab Med
; 60(10): 1661-1668, 2022 09 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-35918785
3.
Prostate Cancer Epigenetic Plasticity and Enhancer Heterogeneity: Molecular Causes, Consequences and Clinical Implications.
Adv Exp Med Biol
; 1390: 255-275, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36107324
4.
The intravenous to oral switch of taxanes: strategies and current clinical developments.
Future Oncol
; 17(11): 1379-1399, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33356545
5.
A prospective observational registry evaluating clinical outcomes of Radium-223 treatment in a nonstudy population.
Int J Cancer
; 147(4): 1143-1151, 2020 08 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31875956
6.
Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial.
BMC Cancer
; 20(1): 884, 2020 Sep 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-32928177
7.
Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer.
Future Oncol
; 16(19): 1371-1384, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-32469606
8.
Concurrent Radiotherapy and Panitumumab after Lymph Node Dissection and Induction Chemotherapy for Invasive Bladder Cancer.
J Urol
; 201(3): 478-485, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30321552
9.
Exposure to Docetaxel in the Elderly Patient Population: a Population Pharmacokinetic Study.
Pharm Res
; 36(12): 181, 2019 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31732882
10.
Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial.
Lancet Oncol
; 18(4): 473-485, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28283282
11.
Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration-resistant prostate cancer patients; a possible time relation.
Prostate
; 76(1): 32-40, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26390914
12.
Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer.
Oncology
; 91(5): 267-273, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27544669
13.
Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin.
World J Urol
; 34(2): 157-62, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26184106
14.
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.
Lancet Oncol
; 15(7): 700-12, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24831977
15.
Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment.
Cancer
; 120(7): 968-75, 2014 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24382803
16.
Occult lymph node metastases in patients with carcinoma invading bladder muscle: incidence after neoadjuvant chemotherapy and cystectomy vs after cystectomy alone.
BJU Int
; 114(1): 67-74, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-24053889
17.
It Takes Two to Tango: The Interplay between Prostate Cancer and Its Microenvironment from an Epigenetic Perspective.
Cancers (Basel)
; 16(2)2024 Jan 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38254784
18.
Agent-based modeling of the prostate tumor microenvironment uncovers spatial tumor growth constraints and immunomodulatory properties.
NPJ Syst Biol Appl
; 10(1): 20, 2024 Feb 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-38383542
19.
Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP Study.
Eur Urol Oncol
; 2024 Apr 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-38664139
20.
Current Routine Testosterone Immunoassays Are Unsuitable for Lowering the General Castration Cutoff Recommendation to <0.7 nmol/l (20 ng/dl).
Eur Urol Open Sci
; 48: 98-100, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36654783